Regulus Therapeutics Inc. (RGLS) Shares Up 3.9%
Regulus Therapeutics Inc. (NASDAQ:RGLS) shares shot up 3.9% during trading on Monday . The company traded as high as $3.83 and last traded at $3.71, with a volume of 304,496 shares traded. The stock had previously closed at $3.57.
A number of research firms have commented on RGLS. Wells Fargo & Co. restated an “outperform” rating on shares of Regulus Therapeutics in a research note on Sunday. FBR & Co restated a “buy” rating and set a $30.00 price target on shares of Regulus Therapeutics in a research note on Sunday, April 17th. BMO Capital Markets restated a “buy” rating on shares of Regulus Therapeutics in a research note on Monday, May 2nd. Chardan Capital began coverage on Regulus Therapeutics in a research note on Wednesday, April 13th. They set a “buy” rating and a $15.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.17.
The company’s 50-day moving average is $4.10 and its 200-day moving average is $5.82. The firm’s market cap is $191.60 million.
Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. On average, equities research analysts expect that Regulus Therapeutics Inc. will post ($1.54) EPS for the current fiscal year.
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.